A report indicates pharma companies do not agree on what research needs to be reported.
Their letter to CMS voices disagreement with the decision to make textbooks and journals reportable under the Sunshine Act.
A poll by consulting firm QPharma indicates doctors are in the dark about what needs to be reported and what will be revealed.
With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
A study finds sales reps find time to talk benefits, but not risks, even when touting black-box drugs; FCC has named its new mHealth director; pharma scaled back its food budgets last year; and AMSA says 18 med schools now ban faculty from speakers bureau participation
BMS fills week's end with shakeup and collaboration news, European regulators tamp down on rare disease drug pricing, association estimates pharma wooed UK docs with $61 million in gifts last year.
AstraZeneca loses in patent court and Pulmicort goes generic, Barbara Ryan joins FTI, Everyday Health and Mayo Clinic expand their advertising alliance, analyst says Ivokana side effect could limit sales
Gift bans or no, students still connect with drug companies, a study has found.
New transparency rules set to lay bare financial ties between physicians and pharma will be a mixed bag for medical education, providers say.
Clinical Research Organizations, marketing research firms, accredited CME providers and lawyers look to be the big winners in CMS's Sunshine Act rule.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.
CMS issued its long-delayed final rule for collecting data on industry payments to physicians, ordering data collection to begin in August and asserting that the federal law preempts state laws.
Abbott releases its 2012 numbers, Sen. Grassley demands Sunshine Act action from CMS and Allergan and Watson flex their purchasing power.
Edelman nabs a GolinHarris exec, CMS submits Sunshine regs and McKesson expands its e-coupon reach.
GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.
As the Massachusetts Department of Public Health deliberates the exact shape of a rule change allowing industry-sponsored meals for physicians in speaker programs, pharma foes and industry advocates are squaring off over the definition of "modest meals and refreshments."
Physicians are reconsidering their participation in industry-sponsored CME, fearful that their inclusion in Sunshine Act databases as having received payments from companies will tarnish their reputations and fuel perceptions of conflicts of interest, a survey has found.
Massachusetts legislators aren't just sick of the Prescriptions Drug Gift Ban -- they're looking to wipe it from the books.
PhRMA's annual meeting in Boston was full of talk about how scientific advances are pushing the boundaries of medicine's potential, but the mood was woe-is-me as members pondered their industry's poor public reputation.
Medical journal coverage of the question of physician-industry relationships is "unbalanced" and may be skewing public policy towards ever-more restrictive safeguards against industry influence.
About 65% of the 1,800 physicians surveyed in a 2009 study discussed in Health Affairs support disclosing potential conflicts of interest to patients.
The Physician Payment Sunshine Act maintains the exclusion for marketing research incentives
The majority of physicians agrees that it's important to disclose to patients any financial relationships with drug and device companies but, research shows, there remains considerable rearguard sentiment to transparency.
The Centers for Medicare and Medicaid Services, now a month overdue to issue draft guidelines for reporting pharma-physician contacts as required under healthcare reform legislation, said the department is working on it, but offered nothing in the way of a timeline.
Eli Lilly reported paying $48.1 million to 45,440 physicians and/or 1,827 healthcare organizations during the first quarter, most of it for research and educational programs.
Thanks to the work of lobbyists, marketing research-related payments are explicitly excluded from Sunshine legislation enacted Tuesday as part of the healthcare overhaul. But the exclusion may not always apply.
GlaxoSmithKline said it paid nearly $15 million in fees in the second quarter to US healthcare professionals for speaking and consulting services.
The House of Representatives' version of the healthcare reform bill, dubbed the America's Affordable Health Choices Act of 2009, includes the provisions of the Physician Payment Sunshine Act, which would mandate sweeping transparency measures for pharmas.